Mount Sinai spinoff aims to develop precision medicine platform: 5 things to know

Becker's Healthcare November 17, 2021
Hannah Mitchell

Linus Biotechnology, a spinoff of New York City-based Mount Sinai Innovation Partners and a precision exposome medicine company, is slated to develop a tech platform with exposome sequencing.

Five things to know:

1. Mount Sinai Innovation Partners and Linus Biotechnology inked an exclusive worldwide licensing agreement with the Icahn School of Medicine at Mount Sinai, according to a Nov. 17 news release.
2. LinusBio expects to develop a technology platform that will build on breakthroughs in exposome sequencing by researchers from Mount Sinai’s Department of Environmental Medicine and Public Health.
3. The spinoff’s program pipeline consists of precision exposome medicine biomarkers and targets discovery across diseases where there are no molecular endpoints available in clinical trials. These diseases include autism...

Today's Sponsors

Today's Sponsor